Tucatinib drug page Clinical trials

Trials with Tucatinib

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

14Trials
4Recruiting
17Countries
2.242Planned patients

Showing 1–14 of 14

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
Recruiting Phase 1 100 patients NCT07318389

To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.

United States Jun 2026 – Nov 2029 Interventional
PRE-ISPY Phase I/II Oncology Platform Program
Recruiting Phase 1 280 patients NCT05868226

PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or me…

United States Feb 2023 – Dec 2031 Interventional
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Recruiting Phase 2 37 patients NCT05672524

The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX), may help participants with rectal cancer.

United States Dec 2022 – Jul 2030 Interventional
Combined with: Trastuzumab
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Recruiting Phase 3 400 patients NCT05253651

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…

United States, Argentina, Australia, Austria and 7 more Oct 2022 – Jul 2030 Interventional
Tucatinib Continuation Study
Not yet recruiting Phase 4 175 patients NCT07768358

The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment. These participants were part of Pfizer-sponso…

Nov 2026 – Mar 2032 Interventional
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Ongoing, not recruiting Phase 2 172 patients NCT06157892

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're …

United States, Australia, Canada, Germany and 6 more May 2024 – Jul 2029 Interventional
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Ongoing, not recruiting Phase 1 200 patients NCT06239467

OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with other…

United States, Belgium, France, Italy and 2 more Feb 2024 – Aug 2027 Interventional
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
Ongoing, not recruiting Phase 1 25 patients NCT05382364

The primary purpose of this study is to characterize the safety and tolerability of tucatinib (MK-7119) in Chinese participants with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, gastric or gastroesophag…

China Jun 2022 – Dec 2026 Interventional
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Ongoing, not recruiting Phase 2 217 patients NCT04579380

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metasta…

United States, Belgium, Germany, Italy and 4 more Jan 2021 – Dec 2026 Interventional
Combined with: FulvestrantTrastuzumab
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Ongoing, not recruiting Phase 2 40 patients NCT04430738

This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It will look at what side effects happen when participants take this combination of drugs. A…

United States, Japan Sept 2020 – Dec 2026 Interventional
Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Finished Phase 2 NCT05356897

This phase II trial studies whether tucatinib combined with trastuzumab and TAS-102 works to shrink tumors in patients with HER2 positive colorectal cancer that has spread to other parts of the body (metastatic) and has one of the followin…

United States Oct 2023 – Sept 2024 Interventional
Combined with: TrastuzumabTrifluridine
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
Finished Phase 2 477 patients NCT05062889

The aims of this study are to evaluate if an intensified adjuvant treatment with FOLFOXIRI could increase the rate of cases with undetectable ct-DNA after chemotherapy and to evaluate if a further adjuvant treatment with Trifluridine/Tipir…

Italy May 2023 – Dec 2029 Interventional
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Finished Phase 1 2 patients NCT05091528

This study is designed to assess the safety and preliminary activity of SBT6050 in combination with trastuzumab deruxtecan (Part 1) or tucatinib plus trastuzumab +/- capecitabine (Part 2). Participants will be enrolled into each Arm based …

United States Feb 2022 – Jul 2022 Interventional
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
Finished Phase 2 117 patients NCT03043313

This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer ha…

United States, Belgium, France, Italy and 1 more Jun 2017 – Nov 2023 Interventional
Combined with: Trastuzumab

Where the recruiting trials are